$140M for New MPM BioVentures Fund
Erin Kutz2/12/10
Boston-based MPM Capital, an investment firm focused on life sciences companies, has raised $140 million for its fifth BioVentures fund, according to regulatory filings. Earlier reports pegged the deal at $69.1 million, but the company amended its original filing this afternoon to indicate the higher total. The firm declined to comment further on the new funding. MPM’s $552 million BioVentures IV fund led a $35 million series B round at the end of January for Alnara Pharmaceuticals, a Cambridge, MA, developer of protein-based treatments for metabolic diseases.
Erin Kutz is an Associate Editor for Xconomy. You can reach her by e-mail at ekutz@xconomy.com or by phone at (617) 252-0700, or follow her on Twitter at @erkutz.
